Schedule 13D ownership disclosure

Prelude Therapeutics, Inc.

Security class unavailable · CUSIP: 74065P101

Event date: 2020-09-24

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
10,121,228
Percent of class
31.1000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-20-110491
Form type
SC 13D
Filer
BAKER BROS. ADVISORS LP
CIK
CIK 1263508
Filed
Sep 30, 2020
Reporting period
Sep 24, 2020
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub